Long-Term Tolerability of Saxagliptin as Add-On Therapy in Type 2 Diabetes (T2D): Pooled Analysis

被引：0
|
作者：
Allen, Elsie
Fleming, Doug
Berglind, Niklas
Donovan, Mark
Ohman, Peter
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1087-P
引用
收藏
页码：A298 / A299
页数：2
相关论文
共 50 条
  • [31] Long-term efficacy with sitagliptin as monotherapy or add-on therapy to metformin: improvement in glycaemic control over 2 years in patients with type 2 diabetes
    Williams-Herman, D.
    Seck, T.
    Golm, G.
    Wang, H.
    Johnson, J.
    Kaufman, K.
    Goldstein, B. J.
    DIABETOLOGIA, 2009, 52 : S296 - S296
  • [32] Long-Term Efficacy with Sitagliptin as Monotherapy or Add-On Therapy to Metformin: Improvement in Glycemic Control over 2 Years in Patients with Type 2 Diabetes
    Williams-Herman, Debora E.
    Seck, Thomas L.
    Golm, Gregory
    Wang, Hong-Wei
    Johnson, Jeremy
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2009, 58 : A144 - A145
  • [33] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Pfuetzner, A.
    Gurieva, I
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 168S - 169S
  • [34] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Gurieva, I.
    Pfuetzner, A.
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 226 - 227
  • [35] COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM
    Eliaschewitz, F. G.
    Asano, E.
    Nita, M. E.
    Rached, R.
    Donato, B. M.
    VALUE IN HEALTH, 2010, 13 (07) : A295 - A295
  • [36] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    DIABETES, 2016, 65 : A293 - A293
  • [37] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
    Anthony H. Barnett
    Bernard Charbonnel
    Jia Li
    Mark Donovan
    Douglas Fleming
    Nayyar Iqbal
    Clinical Drug Investigation, 2013, 33 : 707 - 717
  • [38] Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
    Barnett, Anthony H.
    Charbonnel, Bernard
    Donovan, Mark
    Fleming, Douglas
    Chen, Roland
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 513 - 523
  • [39] Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
    Barnett, A. H.
    Charbonnel, B.
    Li, J.
    Donovan, M.
    Fleming, D.
    DIABETOLOGIA, 2011, 54 : S108 - S109
  • [40] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
    Barnett, Anthony H.
    Charbonnel, Bernard
    Li, Jia
    Donovan, Mark
    Fleming, Douglas
    Iqbal, Nayyar
    CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 707 - 717
12345